Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on ...

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE ...
Yahoo Finance

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
MarketScreener

Wave Life Sciences Initiates Phase 2a Trial of Obesity Drug WVE-007 in Combination With Tirzepatide

Sep. 23 Wave Life Sciences Ltd. Initiates Phase 2A Combination Trial of Wve-007 with Tirzepatide for Obesity CI Sep. 22 Wave Life Sciences Ltd. Announces Appointment of Monika Vnuk as Chief Business ...